Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (ATHE) ) just unveiled an update.
On September 4, 2025, Alterity Therapeutics Limited announced a trading halt on its securities, pending a significant announcement related to a capital raising. The halt is expected to last until the earlier of the announcement release or the commencement of normal trading on September 8, 2025. This move signals a potential strategic financial maneuver that could impact the company’s market position and stakeholder interests.
The most recent analyst rating on (ATHE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Alterity Therapeutics stock, see the ATHE Stock Forecast page.
Spark’s Take on ATHE Stock
According to Spark, TipRanks’ AI Analyst, ATHE is a Neutral.
The overall stock score for Alterity Therapeutics is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows posing significant risks. However, technical analysis indicates strong upward momentum, which partially offsets the negative financial outlook. The poor valuation due to a negative P/E ratio further depresses the score. Without earnings call insights or new corporate events, the score reflects the current financial and technical conditions.
To see Spark’s full report on ATHE stock, click here.
More about Alterity Therapeutics
Alterity Therapeutics Limited is a development stage enterprise in the biotechnology industry, focusing on innovative therapies for neurodegenerative diseases. The company is listed on the Australian Securities Exchange (ASX) and the NASDAQ, indicating a focus on both domestic and international markets.
Average Trading Volume: 82,191
Technical Sentiment Signal: Buy
Current Market Cap: $78.27M
See more insights into ATHE stock on TipRanks’ Stock Analysis page.